Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT04315077 |
Other study ID # |
0519 |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
October 1, 2019 |
Est. completion date |
November 25, 2019 |
Study information
Verified date |
November 2020 |
Source |
Applied Science & Performance Institute |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The purpose of this study will be to examine the effects of Oceanix supplementation on
isometric mid-thigh pull force kinetics and salivary immunoglobulin A (indice of immune
function) following a one-week intense resistance training protocol. The study will be
carried out in a randomized, double-blind, placebo-controlled, parallel manner. Subjects will
be stratified into quartiles based on peak force achieved in the isometric mid-thigh pull
assessment during screen and prior to baseline testing. Subjects from each quartile will be
randomly divided by into treatment and or placebo conditions.
Following randomization, subjects will be baseline tested on isometric mid-thigh pull and
salivary immunoglobulin A. Following baseline testing, subject will be given their respective
supplement conditions and will be instructed to consume one serving (25mg) a day for 21
consecutive days. For days 1 through 14 subjects will be asked to refrain from resistance
training. Subjects will undergo a five day intense resistance training protocol will on day
15 to day 19. Subjects will complete follow-up testing in a manner identical to baseline on
day 20 and 21 (24- and 48-hours post completion of the training protocol).
Description:
The purpose of this study will be to examine the effects of Oceanix supplementation on
isometric mid-thigh pull force kinetics and salivary immunoglobulin A (indice of immune
function) following a one-week intense resistance training protocol. The study will be
carried out in a randomized, double-blind, placebo-controlled, parallel manner. Subjects will
be stratified into quartiles based on peak force achieved in the isometric mid-thigh pull
assessment during screen and prior to baseline testing. Subjects from each quartile will be
randomly divided by into treatment and or placebo conditions. Supplement conditions will be
provided in visually identical capsules and containers. Supplement compliance will be
determined via supplement logs and collection of supplement containers on day 21. Subjects
will be instructed to refrain from consuming other nutritional supplements for the duration
of the study.
Following randomization, subjects will be baseline tested on isometric mid-thigh pull and
salivary immunoglobulin A. Following baseline testing, subject will be given their respective
supplement conditions and will be instructed to consume one serving (25mg) a day for 21
consecutive days. For days 1 through 14 subjects will be instructed to consume their
condition with their first meal of the day, and they will asked to refrain from resistance
training during this time frame. Subjects will undergo a five day intense resistance training
protocol will on day 15 to day 19, and they will be instructed to consume their condition
approximately 30 minutes prior to the training session. Subjects will complete follow-up
testing in a manner identical to baseline on day 20 and 21 (24- and 48-hours post completion
of the training protocol) consuming their condition approximately 30 minutes prior to their
arrival at the laboratory.
The five day resistance training protocol will consist of two lower-, two upper-, and one
full-body workout. Exercise sets performed on the first four days of the protocol will be
targeted will repetition maximum loads such that sets will be perform to or near muscular
failure. On the fifth day of the protocol, subjects will perform sets of bodyweight rear foot
elevated split squats to failure for a total of 10 sets (5 sets with each leg in an
alternating fashion). Subjects will be instructed to maintain the cadence set on an audible
metronome, which will be set at one second downward and one second upward. Failure for these
sets will be defined as 1) volitional muscle failure or 2) failure to complete two
consecutive repetitions at the prescribed metronome cadence. Subjects will rest for one
minute between sets. Prior to all training sessions, subjects will perform a dynamic warm-up,
and following all training sessions, subjects will complete a cool down with static
stretching of the targeted muscle groups with the session. All warm-up, resistance training,
and cool down sessions will be supervised by trained research personnel. All training
sessions will be separated by at least 24-hours.